<DOC>
	<DOCNO>NCT00585910</DOCNO>
	<brief_summary>The purpose study evaluate safety , effectiveness , tolerability atomoxetine OROS methylphenidate , take together , treatment ADHD child adolescent age 6-17 .</brief_summary>
	<brief_title>Study Atomoxetine OROS Methylphenidate Treat Children Adolescents Ages 6-17 With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male female outpatient 6 17 year old . Subjects DSMIV diagnosis ADHD clinical interview , confirm KSADSE ADHD module . Subject DSMIV diagnosis ADHD without previous treatment . Subjects DSMIV diagnosis ADHD clinical history partial response ATMX methylphenidate monotherapy . In phase I , subject CGISeverity least moderate impairment relate ADHD ( CGI &gt; 4 ) . In phase II , subject receive therapeutic dos ATMX least minor improvement clinical picture due ATMX determine operationally ( CGIImprovement score indicate least minor improvement relative offdrug baseline ) include . In phase II , subject receive ATMX also evidence persistent symptom ADHD impairment relate ADHD ( CGISeverity &gt; minor impairment OR ADHD RS &gt; 18 ; AND GAF score &lt; 65 ) Concerta add regimen . Subjects ' parent must provide informed consent subject ' assent . Pregnant nursing female females use proper contraception . Subjects medical condition treatment either jeopardize subject safety affect scientific merit study . Subjects ( family ) appear reliable reporter condition indicate able meet schedule visit duration study . Subjects Mental Retardation Organic Brain Syndromes . Subjects lifetime history psychotic bipolar disorder . Subjects recent current ( past 30 day ) major depressive disorder clinically significant anxiety disorder would potentially necessitate treatment trial . g. Subjects recent evidence ( past 30 day ) suicidality homicidality enrol . Subjects recent history ( e.g . three month ) substance use disorder ; positive urine substance abuse enrol . Subjects tell positive urine substance abuse disclose parent . Subjects take stimulant psychotropics time evaluation . Subjects discontinue current medication regimen ( include ATMX ) , unless authorize supervised treating physician . Treatment stimulant within one week evaluation ; tricyclic antidepressant , bupropion , cholinesterase inhibitor , modafinil , clonidine/guanfacine , lithium/anticonvulsants behavioral control , serotonin reuptake inhibitor ( except fluoxetine ) four week prior entry prohibit . Treatment antipsychotics/neuroleptics fluoxetine 8 week prior entry prohibit . Subjects use prescribed overthecounter concurrent treatment ADHD . Subjects history lack response either ATMX methylphenidate . Subjects history serious adverse event either ATMX methylphenidate .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Strattera</keyword>
	<keyword>Concerta</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>OROS Methylphenidate</keyword>
</DOC>